Market Cap 242.04M
Revenue (ttm) 144.29M
Net Income (ttm) -13.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.41%
Debt to Equity Ratio 7.22
Volume 932,500
Avg Vol 1,839,058
Day's Range N/A - N/A
Shares Out 183.36M
Stochastic %K 38%
Beta 1.28
Analysts Strong Sell
Price Target $4.50

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology
Sector: Healthcare
Phone: (858) 251-4400
Address:
100 Regency Forest Drive, Suite 300, Cary, United States
Braddog
Braddog Feb. 3 at 1:46 PM
$HRTX @BioCurious1 You posted “Management is trying - the vials for easier use - expanded approval for soft tissues” Management has approval for the VAN BUT I don’t know of any “expanded approval for soft tissues”? Where did you get that info from?
1 · Reply
BioCurious1
BioCurious1 Feb. 3 at 5:46 AM
$HRTX some folks here been pumping for years. Can only image in bags of sh** they are holding 😂 🤡 Never fall in love with a stock (and don’t trust chatGPT to do your DD) lol
1 · Reply
BioCurious1
BioCurious1 Feb. 2 at 7:40 PM
$HRTX former bag holder here. What I learned through a lot of D&D is that while Zynrelief is an awesome drug and application, there’s really no market for it. When anti-opioids were all the rage, this had a chance to be its alternative but it never took off as a standard of care for knee surgeries ect. Stryker actually paid for one of the studies for this drug because it would help them sell more knees if they could convince people there’s no addiction risk. The new HRTX C-suite is trying their best to right a ship that isn’t built sound. Unfortunately every science break through isn’t revolutionary . If you wanna check of Barry’s next project, check out CNTB. Not really plugging it but they are set up for a very interesting 2026 with new data coming out. He was the guy who brought this drug to market. He’s since moved to the next project (and hopefully less dilution lol) Best of luck all
2 · Reply
Shooter40
Shooter40 Feb. 2 at 5:41 PM
$HRTX from chatgpt (continued) The real unlock isn’t just one strong December — it’s two clean quarters in a row that confirm the exit rate. Once the market can annualize the run-rate with confidence, the multiple jumps.
1 · Reply
Shooter40
Shooter40 Feb. 2 at 5:37 PM
$HRTX from chatgpt So let’s answer your question cleanly If December numbers are accurate and sustained: Too conservative: $3–4 Reasonable bull base case (12 months): $6–8 Stretch / momentum case: $9–12 Anything below $5 assumes the market still doesn’t believe the story.
0 · Reply
BullMaven
BullMaven Feb. 2 at 3:48 PM
$HRTX volume is building
0 · Reply
Braddog
Braddog Feb. 2 at 2:36 PM
$HRTX Happy Groundhog Day! So appropriate for long investors in Heron! lol 😡😡😡😡😡😡😡
0 · Reply
jacksonjohn750
jacksonjohn750 Feb. 2 at 1:51 PM
$HRTX The shorts have been the smartest here. They held through drop to .75 and rise to 4.. they are still here!!!! They have the most information here
0 · Reply
slayer2408
slayer2408 Feb. 1 at 8:24 PM
$HRTX nobody knows what’s going to happen with this stock. Example: braddog says we will not see $5 without an acceleration in sales. This is not true; we almost saw $4 with minimal sales growth after bottoming at .50
4 · Reply
ReelHeel98
ReelHeel98 Jan. 30 at 1:33 AM
$HRTX I have bought this stock from 12 to 24 to .80 and at this point. WTF! Can we just get back to 5 or 6 and I will get off this train!
5 · Reply
Latest News on HRTX
Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:38 AM EDT - 9 months ago

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript


U.S. District Court Upholds Validity of CINVANTI® Patents

Dec 3, 2024, 4:36 PM EST - 1 year ago

U.S. District Court Upholds Validity of CINVANTI® Patents


Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 10:35 PM EDT - 2 years ago

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript


Heron Therapeutics Is Out Of Survival Mode

Feb 17, 2024, 1:54 AM EST - 2 years ago

Heron Therapeutics Is Out Of Survival Mode


Heron Therapeutics Gets Back On Track

Dec 29, 2023, 3:14 PM EST - 2 years ago

Heron Therapeutics Gets Back On Track


Braddog
Braddog Feb. 3 at 1:46 PM
$HRTX @BioCurious1 You posted “Management is trying - the vials for easier use - expanded approval for soft tissues” Management has approval for the VAN BUT I don’t know of any “expanded approval for soft tissues”? Where did you get that info from?
1 · Reply
BioCurious1
BioCurious1 Feb. 3 at 5:46 AM
$HRTX some folks here been pumping for years. Can only image in bags of sh** they are holding 😂 🤡 Never fall in love with a stock (and don’t trust chatGPT to do your DD) lol
1 · Reply
BioCurious1
BioCurious1 Feb. 2 at 7:40 PM
$HRTX former bag holder here. What I learned through a lot of D&D is that while Zynrelief is an awesome drug and application, there’s really no market for it. When anti-opioids were all the rage, this had a chance to be its alternative but it never took off as a standard of care for knee surgeries ect. Stryker actually paid for one of the studies for this drug because it would help them sell more knees if they could convince people there’s no addiction risk. The new HRTX C-suite is trying their best to right a ship that isn’t built sound. Unfortunately every science break through isn’t revolutionary . If you wanna check of Barry’s next project, check out CNTB. Not really plugging it but they are set up for a very interesting 2026 with new data coming out. He was the guy who brought this drug to market. He’s since moved to the next project (and hopefully less dilution lol) Best of luck all
2 · Reply
Shooter40
Shooter40 Feb. 2 at 5:41 PM
$HRTX from chatgpt (continued) The real unlock isn’t just one strong December — it’s two clean quarters in a row that confirm the exit rate. Once the market can annualize the run-rate with confidence, the multiple jumps.
1 · Reply
Shooter40
Shooter40 Feb. 2 at 5:37 PM
$HRTX from chatgpt So let’s answer your question cleanly If December numbers are accurate and sustained: Too conservative: $3–4 Reasonable bull base case (12 months): $6–8 Stretch / momentum case: $9–12 Anything below $5 assumes the market still doesn’t believe the story.
0 · Reply
BullMaven
BullMaven Feb. 2 at 3:48 PM
$HRTX volume is building
0 · Reply
Braddog
Braddog Feb. 2 at 2:36 PM
$HRTX Happy Groundhog Day! So appropriate for long investors in Heron! lol 😡😡😡😡😡😡😡
0 · Reply
jacksonjohn750
jacksonjohn750 Feb. 2 at 1:51 PM
$HRTX The shorts have been the smartest here. They held through drop to .75 and rise to 4.. they are still here!!!! They have the most information here
0 · Reply
slayer2408
slayer2408 Feb. 1 at 8:24 PM
$HRTX nobody knows what’s going to happen with this stock. Example: braddog says we will not see $5 without an acceleration in sales. This is not true; we almost saw $4 with minimal sales growth after bottoming at .50
4 · Reply
ReelHeel98
ReelHeel98 Jan. 30 at 1:33 AM
$HRTX I have bought this stock from 12 to 24 to .80 and at this point. WTF! Can we just get back to 5 or 6 and I will get off this train!
5 · Reply
slayer2408
slayer2408 Jan. 29 at 4:44 PM
$HRTX I don’t see a benefit in buying options vs shares considering we’re a penny stock
0 · Reply
Shooter40
Shooter40 Jan. 29 at 1:04 PM
$HRTX company just reported the best top line growth in recent history, exceeding expectations. If these results continue, which seems likely given the inflection point in growth that has been achieved, company will generate self sustaining free cash flow going forward with no need for additional equity offerings. No refinancing risk for several years as a result of the refinancing done last 2025.. they have 2 best in class products on the market in early launch that will become standard of care, each of which will generate hundreds of millions in top line line revenues annually for years to come.
2 · Reply
Shooter40
Shooter40 Jan. 28 at 9:03 PM
$HRTX call me crazy. I just bought more
4 · Reply
AlwaysMoneySZN
AlwaysMoneySZN Jan. 28 at 8:51 PM
$HRTX will be in the buy zone again soon IMO. This is a swing traders dream
0 · Reply
BullMaven
BullMaven Jan. 28 at 7:07 PM
$HRTX Q4 will be fantastic. need to get to 2+ .
0 · Reply
Sdwg
Sdwg Jan. 28 at 3:27 PM
$HRTX short interest keeps increasing...
0 · Reply
AlwaysMoneySZN
AlwaysMoneySZN Jan. 28 at 3:03 PM
$HRTX Headed lower, they push it down prior to good news, release good news, stock pops 15% right back to where it was the week or so prior. Rinse and repeat
0 · Reply
Braddog
Braddog Jan. 28 at 2:51 PM
$HRTX I think a lot of us are waiting for EOY earnings. I have been trying to give this a leash til then. But this is UNIVESTABLE. This sell off after the bench trial makes me feel very uneasy. How long of a leash will Rubic and Velan give CC to move the PPS out of the dumpster wish I never heard of this company Where are the $100M’s in sales of Zyn? Years away That’s is where they are
1 · Reply
ovitopo
ovitopo Jan. 28 at 1:30 AM
$HRTX I closed my long position 27000 shares at $1.50. I don't want to hear about Heron.
2 · Reply
Braddog
Braddog Jan. 27 at 11:45 PM
$HRTX Short interest on 1/15 is 35.5M an increase of 4.2%. WTF is going on? Nobody has faith that sales are going to increase dramatically
0 · Reply
Shooter40
Shooter40 Jan. 27 at 8:52 PM
$HRTX I sense a rat trying to gets the bulls nervous on here…..hold strong!
2 · Reply
BulICrunch
BulICrunch Jan. 27 at 5:02 PM
$HRTX Correction: dug into the actual patents-in-suit and this case is about Cinvanti (aprepitant), not Zynrelef. Appreciate the pushback — patent list confirms it. @slayer2408 is completely correct it is cinvanti gotta blame GPT and myself for that one. Thanks for saying something I was really convinced. Well then I guess it is all about ER from now on cuz Cinvanti won’t drive this
3 · Reply